The Gabrail Pharmacology Phase 1 Research Center — Canton, Ohio

The Gabrail Pharmacology Phase 1 Research Center is a clinical research site located in Canton, Ohio, United States 44718.

Crixeo Clinical Trials Trust Score: 10/100 (FAILING). This profile has not yet been claimed by the site owner.

The Gabrail Pharmacology Phase 1 Research Center has participated in 3 clinical trials with 1 currently active.

Therapeutic areas: Advanced Solid Tumor, Solid Tumor, Adult, Solid Tumor.

Sponsors: Xilio Development, Inc., Shanghai Huaota Biopharmaceutical Co., Ltd., NiKang Therapeutics, Inc..

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Canton

Browse all research sites in Ohio · View every site in Canton

Sponsor Feasibility Report

Trust Score: 10/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for The Gabrail Pharmacology Phase 1 Research Center?

The Gabrail Pharmacology Phase 1 Research Center has a Crixeo Trust Score of 10/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has The Gabrail Pharmacology Phase 1 Research Center conducted?

The Gabrail Pharmacology Phase 1 Research Center has 3 clinical trials on record, with 1 currently active. Their work covers Advanced Solid Tumor, Solid Tumor, Adult, Solid Tumor.

Is The Gabrail Pharmacology Phase 1 Research Center accredited by Crixeo Clinical Trials?

The Gabrail Pharmacology Phase 1 Research Center has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about The Gabrail Pharmacology Phase 1 Research Center?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.